Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 5

Bristol-Myers Squibb and Samsung BioLogics have expanded their existing manufacturing agreement, in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at Samsung's Incheon, China manufacturing site. Financial terms of the agreement are not disclosed.

Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.

Source: Bristol-Myers Squibb

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here